Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 31, 2022 - Issue 9
Submit an article Journal homepage
233
Views
1
CrossRef citations to date
0
Altmetric
Original Research

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

Yue Hua Department of Phase I Clinical Trial Unit, First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Hong Zhanga Department of Phase I Clinical Trial Unit, First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Xiaojiao Lia Department of Phase I Clinical Trial Unit, First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Jiajia Maia Department of Phase I Clinical Trial Unit, First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Lizhi Yangb Nanguan District Maternal and Child Health and Family Planning Service Center of Changchun, Changchun, Jilin, ChinaView further author information
,
Jie Yanc Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, ChinaView further author information
,
Ying Lic Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, ChinaView further author information
,
Jingchao Sunc Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, ChinaView further author information
,
Wenjie Xuc Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, ChinaView further author information
,
Shiying Hec Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, ChinaView further author information
,
Jinfeng Lic Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, ChinaView further author information
&
Min Wua Department of Phase I Clinical Trial Unit, First Hospital of Jilin University, Changchun, Jilin, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 977-985 | Received 26 Apr 2021, Accepted 22 Sep 2021, Published online: 08 Nov 2021

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.